Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May 10;6(1):182.
doi: 10.1038/s41392-021-00608-1.

Lenalidomide downregulates ACE2 protein abundance to alleviate infection by SARS-CoV-2 spike protein conditioned pseudoviruses

Siyuan Su #  1   2 , Jianfeng Chen #  1   2 , Ying Wang #  1   2 , Lilly M Wong  3 , Zhichuan Zhu  1   2 , Guochun Jiang  2   3 , Pengda Liu  4   5
Affiliations
Comment

Lenalidomide downregulates ACE2 protein abundance to alleviate infection by SARS-CoV-2 spike protein conditioned pseudoviruses

Siyuan Su et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Inactivation of SPOP/CK1 signaling destabilizes ACE2 proteins to alleviate SARS-CoV-2 S protein conditioned pseudoviral infection. a Immunoblot (IB) analysis of whole cell lysates (WCL) derived from indicated cell lines. b A cartoon illustration to demonstrate that the putative SPOP degron is located within the first five amino acids in the ACE2 signal peptide motif. c IB analyses of WCL derived from indicated cells depleted of endogenous SPOP by lenti-viral shRNAs. Cells were selected with 1 μg/ml puromycin for 72 h to eliminate non-infected cells before cell collection. d IB analyses of WCL and Ni-NTA pulldowns derived from HEK293T cells transfected with indicated DNA constructs. 10 μM MG132 was added to cell culture 10 h prior to cell collection. e Top, an illustration of the ACE2 mutation and deletion generated in this panel. Bottom, IB analyses of WCL and Flag-IPs derived from HEK293T cells transfected with indicated DNA constructs. f IB analyses of WCL derived from UMRC6, RCC4, and UMRC2 cells depleted of indicated endogenous CK1 isoforms by lenti-viral shRNAs. Cells were selected with 1 μg/ml puromycin for 72 h to eliminate non-infected cells before cell collection. g IB analyses of WCL and Flag-IPs derived from HEK293T cells transfected with pLenti-ACE2-HA and Flag-SPOP. Indicated doses of D4476 and 10 μM MG132 was added to cell culture 10 h prior to cell collection. h IB analyses of WCL and Ni-NTA pulldowns derived from HEK293T cells transfected with indicated DNA constructs. 20 or 40 μM D4476 with 10 μM MG132 were added to cell culture 10 h prior to cell collection. i IB analyses of WCL and Ni-NTA pulldowns derived from HEK293T cells transfected with indicated DNA constructs. 10 μM MG132 was added to cell culture 10 h prior to cell collection. j IB analysis of WCL derived from HEK293T cells transfected with indicated CMV-GST-ACE2 constructs. 3 or 30 μM lenalidomide was added to cell culture 10 h prior to cell collection. k IB analyses of WCL and Flag-IPs derived from HEK293T cells transfected with CMV-GST-ACE2 and Flag-SPOP. Indicated doses of lenalidomide was added to cell culture 10 h prior to cell collection. l IB analyses of WCL and Ni-NTA pulldowns derived from HEK293T cells transfected with indicated DNA constructs. 40 μM lenalidomide and 10 μM MG132 were added to cell culture 10 h prior to cell collection. m, n IB analyses of WCL derived from UMRC2 cells treated with indicated doses of CK1 inhibitor D4476 (m) or epiblastin A (n) for 10 h. o–q IB analyses of WCL derived from UMRC2 (o), UMRC6 (p), and Calu-3 (q) cells treated with indicated doses of CK1α PROTAC lenalidomide for 10 h. r A cartoon illustration of a proposed model that lenalidomide targets CK1 for CRBN-mediated degradation, alleviating SPOP binding and protection on ACE2 proteins, therefore leading to reduced ACE2 protein abundance. s IB analyses of WCL derived from endogenous ACE2-depleted UMRC2 cells infected with indicated pLenti-ACE2-HA viruses. t Representative immunofluorescent images using WT- and 3A-ACE2 UMRC2 cells obtained from (s) immune-stained with an HA antibody to indicate ACE2 signals. u Pretreating UMRC2 cells with 80 μM lenalidomide for 24 h reduced infection by GFP expressing SARS-CoV-2 S protein conditioned pseudoviruses in vitro. GFP signals were measured 24 h post-infection. Please refer to “Methods” section for details. Error bars were calculated as mean +/− SD, n = 3. *p < 0.05 (one-way ANOVA test). v IB analyses of WCL derived from UMRC2 cells with indicated treatments. Where indicated, 40 μM lenalidomide was added to cell culture 7 h prior to cell collection. w GFP expressing SARS-CoV-2 S protein conditioned pseudovirus infection and lenalidomide treatment do not significantly affect cell proliferation in vitro determined by CellTiter-Glo assays. Error bars were calculated as mean +/− SD, n = 3. *p < 0.05 (one-way ANOVA test). x Representative immunofluorescent images indicating that lenalidomide pre-treatment reduces infection of UMRC2 cells by GFP expressing SARS-CoV-2 S protein conditioned pseudoviruses in vitro. The bar indicates 50 μm. y Pre-treatment of UMRC2 cells with lenalidomide reduces infection by home-made luciferase-expressing SARS-CoV-2 S protein conditioned pseudoviruses in vitro. UMRC2 cells were treated with 40 μM lenalidomide for 7 h before pseudoviral infection in all groups. Group 1, UMRC2 cells were infected with 500 μL home-made pseudoviruses then treated with 40 μM lenalidomide immediately after spinoculation. Group 2, UMRC2 cells were infected with 500 μL home-made pseudoviruses then treated with 40 μM lenalidomide immediately after spinoculation, followed by refreshing culture with 40 μM lenalidomide 24 h post-spinoculation. Group 3, UMRC2 cells were infected with 500 μL home-made pseudoviruses then treated with 40 μM lenalidomide immediately after spinoculation, followed by refreshing culture with 40 μM lenalidomide 24 and 48 h post-spinoculation, respectively. Viral infection was monitored by RLU (relative light unit) generated in luciferase activity assays. Error bars were calculated as mean +/− SD, n = 2. *p < 0.05 (one-way ANOVA test). z IB analyses of WCL derived from indicated ACE2 expressing UMRC2 cells treated with indicated doses of lenalidomide for 20 h prior to cell collection
See this image and copyright information in PMC

Comment on

References

    1. Zamorano Cuervo N, Grandvaux N. ACE2: evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. Elife. 2020;9:e61390. doi: 10.7554/eLife.61390. - DOI - PMC - PubMed
    1. Shen H, et al. MDM2-mediated ubiquitination of angiotensin-converting enzyme 2 contributes to the development of pulmonary arterial hypertension. Circulation. 2020;142:1190–1204. doi: 10.1161/CIRCULATIONAHA.120.048191. - DOI - PMC - PubMed
    1. Pinto, B. G. G. et al. ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19. J. Infect Dis. 222, 556–563 (2020). - PMC - PubMed
    1. Kronke J, et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature. 2015;523:183–188. doi: 10.1038/nature14610. - DOI - PMC - PubMed
    1. Wang S, et al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res. 2021;31:126–140. doi: 10.1038/s41422-020-00460-y. - DOI - PMC - PubMed

Substances